NVO vs WVE: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
NVO is the larger of the two ($169.20B market cap): the incumbent the market prices for continued execution (10.93x forward earnings, beta 0.37). WVE is the smaller challenger ($521.67M), still expected to post a loss next year: more room to run, but more to prove. If you believe the upside is worth bigger swings, NVO fits (beta 0.37). If you want the steadier ride, WVE fits (beta -1.44).
NVO vs WVE: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | NVO | WVE | What it tells you |
|---|---|---|---|
| Market cap | $169.20B | $521.67M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 10.93 | -2.22 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.37 | -1.44 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 11% of range | 0% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.17 | 1.30 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how NVO and WVE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVO and WVE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVO and WVE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Novo Nordisk (NVO) do?
Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.
What does Wave Life Sciences (WVE) do?
Wave Life Sciences builds oligonucleotide medicines, short synthetic strands of genetic material that silence, edit or splice RNA inside cells. Its PRISM platform spans GalNAc-siRNA (the SpiNA design), RNA editing (AIMers, which recruit the body's own ADAR enzymes to correct a single RNA letter) and splicing. The lead programs are WVE-007, an INHBE-silencing siRNA for obesity; WVE-006, an RNA editing therapy for alpha-1 antitrypsin deficiency (AATD); and WVE-008, an editing program for PNPLA3 I148M liver disease. Older programs in Duchenne (WVE-N531) and Huntington's (WVE-003) are being offered to partners. In August 2026 the company redomiciled from Singapore to Delaware, becoming Wave Life Sciences, Inc.
NVO vs WVE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.
- WVE drivers: WVE-006 and the AATD registrational path; WVE-007 repositioned as a combination and maintenance drug.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and only about 6% in Q3, and the ADR down about 21% over the three months to November 20, 2026. For WVE, the central risk is that WVE-007 never produces meaningful weight loss.
NVO or WVE: which should you pick?
If the story you believe is NVO's (GLP-1 obesity and diabetes demand), NVO is the more direct way to own it; if it is WVE's (WVE-006 and the AATD registrational path), WVE is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVO and WVE guides.
NVO vs WVE: the full fundamentals
NVO. Novo Nordisk once commanded a premium pharma multiple on the strength of GLP-1 growth; at about 9.7x trailing and 11x forward earnings in November 2026 it trades at a discount that reflects slowing sales and share loss to Eli Lilly, even after a Q3 beat and a raised outlook. Trailing net income is lifted by an unusually large Q1 2026, which is one reason forward earnings estimates sit below trailing ones. Figures are reported in Danish kroner (market cap and the ADR dividend in dollars) and should be verified against the latest filings; the next report is due February 3, 2027.
WVE. Wave has no product revenue, so earnings multiples do not apply; the useful lens is enterprise value against pipeline and cash. At ~$2.65 on November 20, 2026, the market cap is ~$524 million, and subtracting ~$431 million of cash leaves ~$93 million for everything else, about 1.3x trailing collaboration revenue and about 1.3 times book value overall. Net loss per share was ~$0.30 in Q3 2026, and analysts expect about -$1.09 for 2026. Analyst targets average ~$16.63, showing that the valuation hinges almost entirely on how WVE-006 and WVE-007 data land.
Headline figures (approximate, November 2026): NVO shows revenue (last four quarters) ~DKK 307 billion (+6% YoY in Q3 2026), revenue (2026 consensus) ~DKK 311 billion, net income (ttm) ~DKK 113 billion, gross margin ~83%; WVE shows revenue (ttm) ~$71 million, q3 2026 revenue ~$13.2 million vs ~$9.9 million expected, q3 2026 eps -$0.30 vs ~-$0.32 expected, net loss (ttm) ~-$211 million.
The bottom line: NVO vs WVE
NVO and WVE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined NVO and WVE exposure against your real portfolio. It is not an investment adviser.
Wondering how NVO or WVE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Novo Nordisk
Ask Walnut's AI anything about NVO and see how it fits what you own.
FAQ
What is the difference between NVO and WVE?
+
Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Wave Life Sciences builds oligonucleotide medicines, short synthetic strands of genetic material that silence, edit or splice RNA inside cells. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is NVO or WVE the better stock?
+
Neither is universally better. NVO is the larger incumbent; WVE is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, NVO or WVE?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both NVO and WVE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of NVO vs WVE?
+
NVO: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and only about 6% in Q3, and the ADR down about 21% over the three months to November 20, 2026. Oral competitors, including Lilly's Foundayo (backed by an EMA panel in October 2026) and Viking's Phase 3 pill, raise the pressure further. Manufacturing capacity has been a persistent constraint, limiting how much demand it can serve. US drug pricing, payer coverage decisions, and potential price negotiation add reimbursement risk to its largest market. As an ADR, NVO carries Danish krone currency exposure and is influenced by European regulation. Patent expiries and the eventual arrival of biosimilar or generic competition loom over the long-term semaglutide economics. Debt has also risen with the capacity build (about DKK 134 billion against about DKK 46 billion of cash at September 30, 2026), and trailing free cash flow of about DKK 33 billion is far below net income. WVE: The central risk is that WVE-007 never produces meaningful weight loss. The Phase 1 data showed body composition changes but little movement on the scale, and the high-BMI Phase 2a and the tirzepatide combination trial may confirm that, which would remove most of the obesity value the market once assigned. WVE-006 must show durable M-AAT levels in larger, longer trials, and competing approaches from Beam Therapeutics and Korro Bio could reach the clinic or market with stronger data. Revenue depends on a single partner, GSK, and its timing is unpredictable, as the ~$2.3 million second quarter showed. Operating expenses rose to ~$79 million a quarter in Q3 2026 and the company has an accumulated deficit of ~$1.48 billion, so further dilution is likely before any product revenue arrives. Law firm Johnson Fistel has advertised an investigation tied to the March 26, 2026 drop, but the October 2026 10-Q states Wave is not party to any material legal proceedings. At ~$2.65 the stock is volatile and sensitive to every data update; it kept falling after the November 2026 ObesityWeek update, which again gave no weight-loss figure.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell NVO or WVE; figures are approximate and dated (as of November 2026). Verify current data before investing.